Chronic low back pain due to disc degeneration (CLBP)
A conservative value for CLBP could be around US$600-US$850m.
Conservatively assume a deal size of US$660m, including US$60m as upfront, ~US$180m in development and regulatory milestones and the balance in sales milestones.
It is assumed,
1.High double digit royalties of 25%.
Some of the existing specialty pharma players who already have existing inflammatory back pain drugs such as Abbvie, JNJ, UCB and Amgen are likely to be more suitable as a partner for CLBP.
----------------------------
CHF product likely to be Fast tracked via RMAT as life threatening
RA products (inflammatory diseases portfolio) is showing positive trial data readouts.
The next few weeks and months will provide a clearer picture.
Chronic low back pain due to disc degeneration (CLBP) A...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |